Patents by Inventor Ronald A. Pruzan

Ronald A. Pruzan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220306660
    Abstract: This invention relates to compounds useful for inhibiting telomere elongation. More specifically, the invention provides nucleotide analogs that are incorporated into telomeres by telomerase thereby inhibiting elongation of telomeres. The compounds are use in treating cancer and other cell proliferative diseases.
    Type: Application
    Filed: March 4, 2022
    Publication date: September 29, 2022
    Inventors: Sergei M. Gryaznov, Ronald A. Pruzan, Krisztina Pongracz
  • Patent number: 11279720
    Abstract: This invention relates to compounds useful for inhibiting telomere elongation. More specifically, the invention provides nucleotide analogs that are incorporated into telomeres by telomerase thereby inhibiting elongation of telomeres. The compounds are use in treating cancer and other cell proliferative diseases.
    Type: Grant
    Filed: February 7, 2020
    Date of Patent: March 22, 2022
    Assignee: Geron Corporation
    Inventors: Sergei M. Gryaznov, Ronald A. Pruzan, Krisztina Pongracz
  • Publication number: 20200283461
    Abstract: This invention relates to compounds useful for inhibiting telomere elongation. More specifically, the invention provides nucleotide analogs that are incorporated into telomeres by telomerase thereby inhibiting elongation of telomeres. The compounds are use in treating cancer and other cell proliferative diseases.
    Type: Application
    Filed: February 7, 2020
    Publication date: September 10, 2020
    Inventors: Sergei M. Gryaznov, Ronald A. Pruzan, Krisztina Pongracz
  • Patent number: 10562926
    Abstract: This invention relates to compounds useful for inhibiting telomere elongation. More specifically, the invention provides nucleotide analogs that are incorporated into telomeres by telomerase thereby inhibiting elongation of telomeres. The compounds are use in treating cancer and other cell proliferative diseases.
    Type: Grant
    Filed: June 22, 2018
    Date of Patent: February 18, 2020
    Assignee: Geron Corporation
    Inventors: Sergei M. Gryaznov, Ronald A. Pruzan, Krisztina Pongracz
  • Publication number: 20190106447
    Abstract: This invention relates to compounds useful for inhibiting telomere elongation. More specifically, the invention provides nucleotide analogs that are incorporated into telomeres by telomerase thereby inhibiting elongation of telomeres. The compounds are use in treating cancer and other cell proliferative diseases.
    Type: Application
    Filed: June 22, 2018
    Publication date: April 11, 2019
    Inventors: Sergei M. Gryaznov, Ronald A. Pruzan, Krisztina Pongracz
  • Patent number: 10035814
    Abstract: This invention relates to compounds useful for inhibiting telomere elongation. More specifically, the invention provides nucleotide analogs that are incorporated into telomeres by telomerase thereby inhibiting elongation of telomeres. The compounds are use in treating cancer and other cell proliferative diseases.
    Type: Grant
    Filed: January 30, 2017
    Date of Patent: July 31, 2018
    Assignee: Geron Corporation
    Inventors: Sergei M. Gryaznov, Ronald A. Pruzan, Krisztina Pongracz
  • Patent number: 9771581
    Abstract: Provided herein are antisense oligonucleotides that can effectively prevent or decrease c-myc protein expression as well as decrease overall rates of cell proliferation in in vitro and mammalian in vivo models of cell proliferative disorders as well as methods for using the same.
    Type: Grant
    Filed: December 2, 2015
    Date of Patent: September 26, 2017
    Assignee: Geron Corporation
    Inventors: Sergei M. Gryaznov, Daria Zielinska, Ronald A. Pruzan, Jeffrey N. Lindquist
  • Publication number: 20170233419
    Abstract: This invention relates to compounds useful for inhibiting telomere elongation. More specifically, the invention provides nucleotide analogs that are incorporated into telomeres by telomerase thereby inhibiting elongation of telomeres. The compounds are use in treating cancer and other cell proliferative diseases.
    Type: Application
    Filed: January 30, 2017
    Publication date: August 17, 2017
    Inventors: Sergei M. Gryaznov, Ronald A. Pruzan, Krisztina Pongracz
  • Patent number: 9593137
    Abstract: This invention relates to compounds useful for inhibiting telomere elongation. More specifically, the invention provides nucleotide analogs that are incorporated into telomeres by telomerase thereby inhibiting elongation of telomeres. The compounds are useful in treating cancer and other cell proliferative diseases.
    Type: Grant
    Filed: December 21, 2012
    Date of Patent: March 14, 2017
    Assignee: Geron Corporation
    Inventors: Sergei M. Gryaznov, Ronald A. Pruzan, Krisztina Pongracz
  • Publication number: 20160186173
    Abstract: Provided herein are antisense oligonucleotides that can effectively prevent or decrease c-myc protein expression as well as decrease overall rates of cell proliferation in in vitro and mammalian in vivo models of cell proliferative disorders as well as methods for using the same.
    Type: Application
    Filed: December 2, 2015
    Publication date: June 30, 2016
    Inventors: Sergei M. GRYAZNOV, Daria ZIELINSKA, Ronald A. PRUZAN, Jeffrey N. LINDQUIST
  • Patent number: 9228189
    Abstract: Provided herein are antisense oligonucleotides that can effectively prevent or decrease c-myc protein expression as well as decrease overall rates of cell proliferation in in vitro and mammalian in vivo models of cell proliferative disorders as well as methods for using the same.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: January 5, 2016
    Assignee: Geron Corporation
    Inventors: Sergei M. Gryaznov, Daria Zielinska, Ronald A. Pruzan, Jeffrey N. Lindquist
  • Publication number: 20150299232
    Abstract: This invention relates to compounds useful for inhibiting telomere elongation. More specifically, the invention provides nucleotide analogs that are incorporated into telomeres by telomerase thereby inhibiting elongation of telomeres. The compounds are useful in treating cancer and other cell proliferative diseases.
    Type: Application
    Filed: December 21, 2012
    Publication date: October 22, 2015
    Inventors: Sergei M. Gryaznov, Ronald A. Pruzan, Krisztina Pongracz
  • Publication number: 20140121261
    Abstract: Provided herein are antisense oligonucleotides that can effectively prevent or decrease c-myc protein expression as well as decrease overall rates of cell proliferation in in vitro and mammalian in vivo models of cell proliferative disorders as well as methods for using the same.
    Type: Application
    Filed: March 14, 2013
    Publication date: May 1, 2014
    Inventors: Sergei M. GRYAZNOV, Daria Zielinska, Ronald A. Pruzan, Jeffrey N. Lindquist
  • Patent number: 7585966
    Abstract: This invention provides inhibitory polynucleotides, such as antisense molecules, directed against accessible regions in the telomerase ribonucleoprotein. The polynucleotides are useful for inhibiting the activity of telomerase in cells and for treating cancer.
    Type: Grant
    Filed: November 8, 1999
    Date of Patent: September 8, 2009
    Assignee: Geron Corporation
    Inventors: James T. Kealey, Ronald Pruzan, Scott L. Weinrich
  • Publication number: 20080213812
    Abstract: Methods and compositions are provided for modulating, e.g., increasing or decreasing, the expression of telomerase reverse transcriptase (TERT). In the subject methods, the binding interaction of the TERT Site C repressor site with a Site C repressor protein complex made up of one or more proteins is modulated to achieve the desired change in TERT expression. A feature of the subject invention is that the target Site C repressor protein complex includes an LSF protein. The subject methods and compositions find use in a variety of different applications, including the immortalization of cells, the production of reagents for use in life science research, therapeutic applications; therapeutic agent screening applications; and the like.
    Type: Application
    Filed: January 18, 2008
    Publication date: September 4, 2008
    Inventors: William H. Andrews, Laura Briggs, Christopher Foster, Hamid Mohammadpour, Stephanie Fraser, David Monda, Lancer Brown, Frederick M. Hahn, Ronald Pruzan, David Schooley, Jason March
  • Publication number: 20060166254
    Abstract: This invention provides purified telomerase and methods of purifying it. The methods involve the use of several sequential steps, including the use of matrices that bind molecules bearing negative charges, matrices that bind molecules bearing positive charges, intermediate-selectivity matrices, methods that separate molecules based on their size, shape, or buoyant density, and by affinity purification.
    Type: Application
    Filed: March 13, 2006
    Publication date: July 27, 2006
    Inventors: Scott Weinrich, Edward Atkinson, Serge Lichtsteiner, Alain Vasserot, Ronald Pruzan
  • Patent number: 7067283
    Abstract: This invention provides purified telomerase and methods of purifying it. The methods involve the use of several sequential steps, including the use of matrices that bind molecules bearing negative charges, matrices that bind molecules bearing positive charges, intermediate-selectivity matrices, methods that separate molecules based on their size, shape, or buoyant density, and by affinity purification.
    Type: Grant
    Filed: March 26, 2004
    Date of Patent: June 27, 2006
    Assignee: Geron Corporation
    Inventors: Scott L. Weinrich, Edward M. Atkinson, III, Serge P. Lichtsteiner, Alain P. Vasserot, Ronald A. Pruzan
  • Publication number: 20050089883
    Abstract: This invention provides purified telomerase and methods of purifying it. The methods involve the use of several sequential steps, including the use of matrices that bind molecules bearing negative charges, matrices that bind molecules bearing positive charges, intermediate-selectivity matrices, methods that separate molecules based on their size, shape, or buoyant density, and by affinity purification.
    Type: Application
    Filed: March 26, 2004
    Publication date: April 28, 2005
    Inventors: Scott Weinrich, Edward Atkinson, Serge Lichtsteiner, Alain Vasserot, Ronald Pruzan
  • Patent number: 6787133
    Abstract: This invention provides purified telomerase and methods of purifying it. The methods involve the use of several sequential steps, including the use of matrices that bind molecules bearing negative charges, matrices that bind molecules bearing positive charges, intermediate-selectivity matrices, methods that separate molecules based on their size, shape, or buoyant density, and by affinity purification.
    Type: Grant
    Filed: December 24, 2002
    Date of Patent: September 7, 2004
    Assignee: Geron Corporation
    Inventors: Scott L. Weinrich, Edward M. Atkinson, III, Serge P. Lichtsteiner, Alain P. Vasserot, Ronald A. Pruzan
  • Publication number: 20030186282
    Abstract: This invention provides purified telomerase and methods of purifying it. The methods involve the use of several sequential steps, including the use of matrices that bind molecules bearing negative charges, matrices that bind molecules bearing positive charges, intermediate-selectivity matrices, methods that separate molecules based on their size, shape, or buoyant density, and by affinity purification.
    Type: Application
    Filed: December 24, 2002
    Publication date: October 2, 2003
    Inventors: Scott L. Weinrich, Edward M. Atkinson, Serge P. Lichtsteiner, Alain P. Vasserot, Ronald A. Pruzan